Learn Why The Bull Case For Pacira BioSciences Shares Could Change Following Earnings Results

Simply Wall St.11-08

Pacira BioSciences reported third quarter 2026 revenue of US$176.65 million and net income of US$28.52 million, with diluted EPS from continuing operations of US$0.70, alongside nine month revenue of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2681584844?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice2-card/1788952923351","is_english":true,"pubTime":"2026-11-08 01:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681584844","market":"nz","top_or_hot":-1,"title":"Learn Why The Bull Case For Pacira BioSciences Shares Could Change Following Earnings Results","media":"Simply Wall St.","content":"<div>\n<p>Pacira BioSciences reported third quarter 2026 revenue of US$176.65 million and net income of US$28.52 million, with diluted EPS from continuing operations of US$0.70, alongside nine month revenue of ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/learn-why-the-bull-case-for-pacira-biosciences-shares-could\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Learn Why The Bull Case For Pacira BioSciences Shares Could Change Following Earnings Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLearn Why The Bull Case For Pacira BioSciences Shares Could Change Following Earnings Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-08 01:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/learn-why-the-bull-case-for-pacira-biosciences-shares-could><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pacira BioSciences reported third quarter 2026 revenue of US$176.65 million and net income of US$28.52 million, with diluted EPS from continuing operations of US$0.70, alongside nine month revenue of ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/learn-why-the-bull-case-for-pacira-biosciences-shares-could\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DECU","symbol_name":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/learn-why-the-bull-case-for-pacira-biosciences-shares-could","article_id":"2681584844","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice2-card/1788952923351"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcrx/pacira-biosciences/news/learn-why-the-bull-case-for-pacira-biosciences-shares-could","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2681584844","pubTimestamp":1794072318,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BBailey PembertonNovember 7, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","RGLO":"Global Equity Active ETF","VOTE":"TCW Transform 500 ETF","VGFPF":"Vanguard Funds PLC","GXDW":"Global X Dorsey Wright Thematic ETF","BK4007":"制药","JOYT":"JPMorgan Equity and Options Total Return ETF","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","PCRX":"Pacira Pharmaceuticals","PMDE":"PGIM S&P 500 Max Buffer ETF - December"},"translate_title":"了解为什么 Pacira BioSciences 股票的牛市可能会在盈利结果后发生变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VOTE":0.9,"PCRX":0.9,"DECU":0.9,"JOYT":0.9,"VGFPF":0.9,"PMDE":0.9,"RGLO":0.9,"FEBU":0.9,"GXDW":0.9},"content_text":"Pacira BioSciences reported third quarter 2026 revenue of US$176.65 million and net income of US$28.52 million, with diluted EPS from continuing operations of US$0.70, alongside nine month revenue of US$546.43 million and net income of US$36.09 million. The sharp step up in earnings relative to roughly flat revenue points to meaningful shifts in cost control, product mix or pricing that change how efficiently Pacira BioSciences converts sales into profit. Now the focus turns to how Pacira BioSciences' investment narrative adapts to this stronger profitability profile, especially the jump in net income.  Pressure test Pacira BioSciences' earnings jump by comparing it with a hand picked group of financially resilient businesses using the 29 resilient stocks with low risk scores. AdvertisementPacira BioSciences Investment Narrative Recap For Pacira BioSciences, the core belief is that EXPAREL and ZILRETTA can keep gaining traction in outpatient and ambulatory settings, while the early gene therapy work on PCRX-201 eventually broadens the pain and musculoskeletal franchise. The latest results show net income and earnings per share scaling faster than revenue, which points to a business that is currently converting sales into profit more efficiently. The near term swing factor is whether this profitability step up is sustainable as reimbursement, procedure volumes and product mix move around quarter to quarter. The biggest risk remains heavy reliance on EXPAREL and reimbursement support, with the NOPAIN Act expiry in 2027 and any slower than expected adoption at new providers both capable of cooling that earnings momentum. The stand out announcement tied to this discussion is the third quarter 2026 report itself. Pacira BioSciences posted US$176.65 million of quarterly revenue against US$179.52 million a year earlier, yet net income moved to US$28.52 million from US$5.43 million, with diluted EPS from continuing operations at US$0.70 versus US$0.12. Over the first nine months of 2026, the business generated US$546.43 million in revenue and US$36.09 million in net income, compared with US$529.54 million and US$5.40 million in the prior period. For you as an investor, the question is whether this improved earnings profile is a sign that Pacira BioSciences can support future R&D on assets like PCRX-201 and PCRX-2002 while still managing the reimbursement and product concentration risks already on the radar. Pacira BioSciences' current earnings are US$14.6 million, with analysts assuming revenue growth of 5.5% per year and consensus earnings of US$70.8 million by 2029. This implies roughly a 5x increase in earnings from today and forecast revenue of US$875.0 million in that same year. Uncover why Pacira BioSciences' fair value indicates an 8% potential downside to its current price, which leaves little room for error. NasdaqGS:PCRX 1-Year Stock Price Chart Exploring Other Perspectives Pacira BioSciences looks very different if you focus on the bearish angle that rising R&D could squeeze profits. The lowest analysts were penciling in 3.1% annual revenue growth and earnings of about US$63.8 million by 2029 before this earnings surprise. That more cautious story may shift, so explore several viewpoints before deciding what makes sense to you. Explore 2 other Pacira BioSciences fair value estimates, including one that suggests as much as 8% downside from the current price. Decide For Yourself Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.  A great starting point for your Pacira BioSciences research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision. See our latest analysis for Pacira BioSciences. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Pacira BioSciences' overall financial health at a glance.  Looking For More Investment Ideas Beyond Pacira BioSciences? Once you have a view on Pacira BioSciences, it often helps to widen the lens and compare it with other businesses that fit different risk, income, or valuation profiles using the Simply Wall St Screener.  If you want a starting point for potential mispricing opportunities, check out a curated set of 39 high quality undervalued stocks that pair solid fundamentals with compressed expectations. For readers who care about balance sheet strength first and share price second, scan the list of solid balance sheet and fundamentals (24 results) to focus on companies with sturdier financial foundations. If you prefer to hunt where fewer investors are looking, use the 19 high quality undiscovered gems and focus on under-followed businesses with strong underlying metrics.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2681584844","isCrawlerRequest":true}